Navigation Links
Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire
Date:2/15/2017

JUPITER, Fla., Feb. 15, 2017 /PRNewswire/ -- Charleston Laboratories, Inc. announced today that Mark A. Mannebach, Ph.D., R.Ph has joined its team as its Vice President of Global Regulatory Affairs & Quality Assurance.  In his role, Mark will oversee and manage all regulatory submissions and renewals and will be responsible for developing the technical requirements of supply and quality agreements and other external contracts, specifically in relation to Charleston Laboratories' pipeline of products that address unmet needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Induced Nausea and Vomiting (MINV), including co-promotion activities under its collaboration with Daiichi Sankyo.

"We're proud to add Mark to our already impressive senior leadership team," said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories.  "Mark's experience in regulatory and quality, coupled with his experience in the pain management industry, will make him a key member of the team."

Mark has more than 30 years of experience in the pharmaceutical industry in a variety of leadership roles at various major pharmaceutical companies including Parke-Davis/Warner-Lambert, Pharmacia, Baxter and Pfizer. For the past 8 years, Mark was the Vice President of Global Regulatory Affairs at Mallinckrodt where he spent a significant amount of his time overseeing the pain management portfolio.  Mark has extensive experience working with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) on a number of NDAs including 505(b)(2) applications.  Mark had responsibility for the NDAs for the approved pain products Exalgo, Pennsaid (both 1.5% & 2% topical solutions), Xartemis XR, and Ofirmev.

"I was intrigued by the opportunity that Charleston Laboratories' pipeline and commercial strategy provides me professionally, to continue working in pain management," stated Dr. Mannebach.  "I'm honored to join a team with such deep experience and a commitment to clinical and commercial excellence."

About Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research, development and commercialization of novel pain products to prevent the burdensome side effects related to opioid analgesics and other analgesic products.  In August 2014, the Company entered a strategic collaboration with Daiichi Sankyo for the development and U.S. commercialization of Charleston Laboratories' investigational hydrocodone-based products, including its lead candidate CL-108.

Charleston Laboratories' product pipeline seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).  Charleston Laboratories intends to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit www.charlestonlabs.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charleston-laboratories-inc-announces-senior-global-regulatory-hire-300407320.html


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
2. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. kondigt uitbreiding mogelijkheden en capaciteiten voor steriele productie medicijnen in Charleston, SC aan
3. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Announces Expanded Capabilities and Capacity for Sterile Drug Product Manufacturing in Charleston, SC
4. The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion
5. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints
6. Charleston Area Medical Center Integrates Smart Pump Technology to Advance Patient Safety
7. Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board
8. Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charlestons Second Product, CL-H1T
9. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting
10. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
11. Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... the Centers for Disease Control and Prevention (CDC), influenza vaccination should ... helping communities across Massachusetts , Connecticut ... shots through the end of the month. *Some exclusions apply ... ... is by the end of October, according to the Centers for Disease ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):